Apellis Pharmaceuticals shares are trading lower after Wedbush maintained a Neutral rating on the stock and lowered its price target from $32 to $29.
Portfolio Pulse from Benzinga Newsdesk
Wedbush has maintained a Neutral rating on Apellis Pharmaceuticals and lowered its price target from $32 to $29. This has led to a decrease in Apellis Pharmaceuticals' share price.
August 07, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' share price has dropped following Wedbush's decision to maintain a Neutral rating and lower its price target from $32 to $29.
The decrease in Apellis Pharmaceuticals' share price is directly linked to Wedbush's decision to lower its price target for the company. This suggests that investors are reacting negatively to the revised price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100